A number of the world’s largest pharmaceutical firms have announced strategies to address the newly identified Covid-19 variant, dubbed Omicron, including plans to alter existing vaccines and develop new boosters.
With the World Health Organization (WHO) designating Omicron the latest “variant of concern” following an emergency meeting on Friday, warning that the highly mutated strain could be more infectious than those seen before, Big Pharma quickly launched into PR-mode, as several firms rushed to outline how they would combat the new variant.
Pfizer – which has produced one of the world’s most commonly used Covid immunizations alongside its German partner BioNTech – told Fox Business that it is “remaining vigilant” and “constantly” monitoring new variants that could “potentially escape protection” from its vaccine.
“In the event that [a] vaccine-escape variant emerges, Pfizer and BioNTech expect to be able to develop and produce a tailor-made vaccine against that variant in approximately 100 days, subject to regulatory approval,” the company added, though it did not say whether any specific research had been conducted into Omicron so far.
BioNTech, in a separate statement, noted that Omicron “differs significantly from previously observed variants as it has additional mutations located in the spike protein,” referring to the mechanism by which the coronavirus gains access to host cells and causes infection. The company also said that a so-called “escape variant” could “require an adjustment of our vaccine if the variant spreads globally.”
Moderna and Johnson & Johnson, two other major Covid vaccine developers, issued similar missives on Friday, with the latter company stating that it’s already testing a booster shot for healthy adults that contains twice the vaccine dosage than what is currently approved. Moderna also said that it is now studying two booster candidates specially designed to “anticipate mutations such as those that have emerged in the Omicron variant.”
J&J, whose single-dose vaccine differs from the others on the market, also told Fox that it is testing its Janssen immunization efficacy against Omicron and “closely monitoring” mutations in the virus’ spike protein.
“It’s very important to investigate the new variant,” acknowledged Kirill Dmitriev, the head of the Russian Direct Investment Fund (RDIF), which bankrolled the development of the Sputnik V vaccine, in an interview with RT on Friday. If it turns out that the strain is resistant to current vaccines, he voiced confidence that Russian scientists could “really quickly adapt Sputnik V to the new variant.”
Following a meeting with Chinese researchers to discuss the possibility of combined immunizations, Dmitriev also called for deeper international cooperation in creating a diversified portfolio of vaccines for combating more dangerous strains.
The WHO’s designation of Omicron, also known as the B.1.1.529 variant, triggered a near-global panic on Friday, including travel restrictions in countries across several continents and tanking stock markets around the world. Despite the alarm, however, little is yet known about the new strain – nor whether it is more transmissible or deadly compared to other variants – and the WHO has stated it may take several weeks of research to begin answering those questions.
source: RT
Împotriva articolelor redacției noastre, persoanele nemulțumite pot formula Contestație în termen de 10 zile de la publicarea articolului, la judecătoria Orășenească nr. 1 München Bayern Deutschland, in conformitate cu Legea federală Germană. Considerăm că nu se pot formula acțiuni la instanțele din România deoarece nici o persoană care activează în trustul nostru nu poate fi extrasă de sub jurisdicția federală germană. Considerăm că redacția noastră nu răspunde în fața autorităților din România ci doar celor federale sau civile germane. deoarece legea română nu are efecte de extraneitate asupra redacției chiar dacă subiectul știrilor face obiectul unor evenimente sau persoane din România și sunt scrise în limba română. Limba română nu este izvor de extraneitate a legii.
absolvent WEB DESIGN Academia Britanică de Comunicare Iasi - absolvent COMUNICARE IN AFACERI Academia Britanica de Afaceri si Comunicare -absolvent JURNALISM EDITORIAL - London School University - 2019 inscris la echivalare diploma la Universitatea Politehnica Timisoara - absolvent studii de Drept Universitatea Europeană Drăgan, cursuri in Drept la Universitatea de Vest Timisoara, absolvent studii de proiectare, pastor coordonator in Biserica Protestanta Evanghelica,
Android Developer pe Google Play și plugin developer la Oxwall, creator de teme Wordpress și Oxwall, operator Wordpress, Drupal, Oxwall, Osclass, Moodle, tehnologii HTML și PHP
Nurses and operating room staff have taken to the streets across France to demand more pay and greater recognition for their work, with some hospitals forced to only undertake emergency operations as personnel strike. On Thursday, state-certified nurses and operating room nurses went on strike across the country, taking their cause to the streets and […]
Chinese lung cancer drug slow-walked because test subjects were Asian The review of an affordable monoclonal antibody drug for treating lung cancer, which had previously been tested in China, has been stalled in the US, a report by the Daily Wire said on Monday. The Food and Drug Administration (FDA) explains the issue by the […]
A Japanese medical facility placed the acceptance of new patients on hold after a cyber intrusion The municipal Handa Hospital in the small town of Tsurugi in western Japan was hit by a ransomware attack at the end of October. The Mainichi Shimbun newspaper reported at the time that one day, many of the hospital’s […]
